Study #2022-0394
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, And Efficacy Of Mosunetuzumab Or Glofitamab In Combination With CC-220 And CC-99282 In Patients With B-Cell Non-Hodgkin Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
SC Mosunetuzumab, Iberdomide, Golcadomide, Tocilizumab, IV Glofitamab, Obinutuzumab
Description
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Hodgkin Lymphoma
Study phase:
Phase I
Physician name:
Jason Westin
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-929-4217
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.